Roche struck a deal to license an ALK7-targeting siRNA program from China-based Rona Therapeutics, aiming to expand its RNAi pipeline in obesity and metabolic disease. The agreement includes upfront and milestone payments that could reach as high as $1.06 billion, plus tiered royalties. The structure reinforces a strategic pattern: rather than limiting RNAi efforts to hepatic targets, Roche is seeking delivery and activity in cardiometabolic biology where mechanism needs careful translation. The deal was described as the second China-to-West licensing transaction for an ALK7 RNAi asset this year. For industry watchers, the announcement also highlights continued pharma focus on obesity mechanisms that could preserve lean mass while reducing fat—an area where clinical endpoints and safety profiles will likely determine long-term viability.